Exact Sciences Stock Forecast, Price & News

-0.84 (-0.85 %)
(As of 05/11/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume2.63 million shs
Average Volume1.69 million shs
Market Capitalization$16.81 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive EXAS News and Ratings via Email

Sign-up to receive the latest news and ratings for Exact Sciences and its competitors with MarketBeat's FREE daily newsletter.

Exact Sciences logo

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype MAP, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.


See More Headlines

Industry, Sector and Symbol

Industry Commercial physical research
Current SymbolNASDAQ:EXAS
Year Founded1995

Sales & Book Value

Annual Sales$876.29 million
Book Value$17.62 per share


Net Income$-83,990,000.00




Market Cap$16.81 billion
Next Earnings Date7/29/2021 (Estimated)

Social Links


Overall MarketRank

1.96 out of 5 stars

Medical Sector

80th out of 2,045 stocks

Commercial Physical Research Industry

2nd out of 42 stocks

Analyst Opinion: 4.4Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Exact Sciences (NASDAQ:EXAS) Frequently Asked Questions

Is Exact Sciences a buy right now?

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Exact Sciences in the last year. There are currently 3 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Exact Sciences stock.
View analyst ratings for Exact Sciences
or view top-rated stocks.

What stocks does MarketBeat like better than Exact Sciences?

Wall Street analysts have given Exact Sciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Exact Sciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Exact Sciences' next earnings date?

Exact Sciences is scheduled to release its next quarterly earnings announcement on Thursday, July 29th 2021.
View our earnings forecast for Exact Sciences

How were Exact Sciences' earnings last quarter?

Exact Sciences Co. (NASDAQ:EXAS) released its quarterly earnings results on Monday, May, 3rd. The medical research company reported ($0.18) EPS for the quarter, beating analysts' consensus estimates of ($1.04) by $0.86. The medical research company earned $402.10 million during the quarter, compared to analysts' expectations of $394.66 million. Exact Sciences had a negative trailing twelve-month return on equity of 11.71% and a negative net margin of 25.27%. The company's quarterly revenue was up 15.6% on a year-over-year basis. During the same period in the previous year, the business earned ($0.71) EPS.
View Exact Sciences' earnings history

How has Exact Sciences' stock price been impacted by COVID-19 (Coronavirus)?

Exact Sciences' stock was trading at $57.82 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, EXAS stock has increased by 69.5% and is now trading at $98.00.
View which stocks have been most impacted by COVID-19

What guidance has Exact Sciences issued on next quarter's earnings?

Exact Sciences updated its FY 2021 earnings guidance on Tuesday, May, 11th. The company provided earnings per share guidance of - for the period. The company issued revenue guidance of $1.69 billion-$1.74 billion, compared to the consensus revenue estimate of $1.72 billion.

What price target have analysts set for EXAS?

14 analysts have issued 1 year price objectives for Exact Sciences' shares. Their forecasts range from $120.00 to $226.00. On average, they anticipate Exact Sciences' share price to reach $157.36 in the next twelve months. This suggests a possible upside of 60.6% from the stock's current price.
View analysts' price targets for Exact Sciences
or view top-rated stocks among Wall Street analysts.

Who are Exact Sciences' key executives?

Exact Sciences' management team includes the following people:
  • Mr. Kevin T. Conroy, Chairman, Pres & CEO (Age 55, Pay $1.82M)
  • Mr. Jeffrey T. Elliott CFA, Chief Financial Officer (Age 43, Pay $701.77k)
  • Ms. Ana Hooker, Sr. VP of Operations (Age 55, Pay $627.49k)
  • Mr. D. Scott Coward, Chief Admin. Officer, Sr. VP, Gen. Counsel & Sec. (Age 56, Pay $741.87k)
  • Mr. Jake Orville, Sr. VP of Pipeline (Age 47, Pay $769.63k)
  • Mr. G. Bradley Cole, Gen. Mang. of Precision Oncology (Age 65, Pay $1.23M)
  • Mr. Gary Frings, Chief Information Officer
  • Dr. Scott C. Johnson Ph.D., Chief Science Officer and Sr. VP of R&D
  • Ms. Megan Jones, Associate Mang. of Investor Relations
  • Mr. Tim Caprez, Chief Compliance Counsel & VP

What is Kevin T. Conroy's approval rating as Exact Sciences' CEO?

141 employees have rated Exact Sciences CEO Kevin T. Conroy on Kevin T. Conroy has an approval rating of 97% among Exact Sciences' employees. This puts Kevin T. Conroy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Exact Sciences' key competitors?

What other stocks do shareholders of Exact Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Exact Sciences investors own include Novavax (NVAX), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), (CRM), PayPal (PYPL), Square (SQ), Advanced Micro Devices (AMD), The Walt Disney (DIS) and AbbVie (ABBV).

What is Exact Sciences' stock symbol?

Exact Sciences trades on the NASDAQ under the ticker symbol "EXAS."

Who are Exact Sciences' major shareholders?

Exact Sciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (2.54%), Artisan Partners Limited Partnership (1.57%), Sumitomo Mitsui Trust Holdings Inc. (1.58%), Nikko Asset Management Americas Inc. (1.30%), New York State Common Retirement Fund (0.36%) and Swiss National Bank (0.36%). Company insiders that own Exact Sciences stock include G Bradley Cole, Graham Peter Lidgard, Jacob A Orville, James Edward Doyle, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Mark Stenhouse, Sarah Condella, Scott C Johnson and Torsten Hoof.
View institutional ownership trends for Exact Sciences

Which major investors are selling Exact Sciences stock?

EXAS stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Artisan Partners Limited Partnership, Wasatch Advisors Inc., Factory Mutual Insurance Co., Fiera Capital Corp, C WorldWide Group Holding A S, HighTower Advisors LLC, and Handelsbanken Fonder AB. Company insiders that have sold Exact Sciences company stock in the last year include Graham Peter Lidgard, Jacob A Orville, James Edward Doyle, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Sarah Condella, and Torsten Hoof.
View insider buying and selling activity for Exact Sciences
or view top insider-selling stocks.

Which major investors are buying Exact Sciences stock?

EXAS stock was bought by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., Principal Financial Group Inc., Jennison Associates LLC, Scout Investments Inc., Banque Pictet & Cie SA, and New York State Common Retirement Fund.
View insider buying and selling activity for Exact Sciences
or or view top insider-buying stocks.

How do I buy shares of Exact Sciences?

Shares of EXAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Exact Sciences' stock price today?

One share of EXAS stock can currently be purchased for approximately $98.00.

How much money does Exact Sciences make?

Exact Sciences has a market capitalization of $16.81 billion and generates $876.29 million in revenue each year. The medical research company earns $-83,990,000.00 in net income (profit) each year or ($1.49) on an earnings per share basis.

How many employees does Exact Sciences have?

Exact Sciences employs 4,800 workers across the globe.

When was Exact Sciences founded?

Exact Sciences was founded in 1995.

What is Exact Sciences' official website?

The official website for Exact Sciences is

Where are Exact Sciences' headquarters?

Exact Sciences is headquartered at 5505 ENDEAVOR LANE, MADISON WI, 53719.

How can I contact Exact Sciences?

Exact Sciences' mailing address is 5505 ENDEAVOR LANE, MADISON WI, 53719. The medical research company can be reached via phone at 608-535-8815 or via email at [email protected]

This page was last updated on 5/11/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.